“Fourth quarter of 2024 marked a standout finish to the year, generating $25 million in revenue and leading to annual revenue of $85.9 million,” said Paul Levesque, President and Chief Executive Officer. “Our bottom line was even stronger, delivering a positive Adjusted EBITDA for the quarter of $7.8 million, up 56% over fourth quarter of 2023 and a full year result surpassing $20 million in Adjusted EBITDA, as compared to negative $3 million in 2023. Our financial success was rewarded by $75 million in new credit facilities with TD Bank and Investissement Quebec, highlighting confidence in our longer-term growth strategy, which is to strengthen and scale our commercial business underpinned by our HIV portfolio. We witnessed unprecedented demand for EGRIFTA SV(R) this past year resulting in full-year sales of $60.1 million dollars, which represents 12% growth year-over-year. We will continue to manufacture additional batches of EGRIFTA SV(R) until the anticipated transition to the F8 formulation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THTX:
- Is THTX a Buy, Before Earnings?
- Theratechnologies Resumes EGRIFTA SV® Distribution Following FDA Approval
- Theratechnologies upgraded to Buy from Speculative Buy at Mackie Research
- Theratechnologies Resumes EGRIFTA SV® Distribution Following FDA Clearance
- Theratechnologies to resume distribution of EGRIFTA